대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Proteomic and Metabolomic Mediators of Visceral Adiposity-Associated Chronic Kidney Disease: A Large-Scale Prospective Cohort Study
저자	Hyo Jeong Kim
출판정보	2026; 2026(1):
키워드	Chronic kidney disease, Visceral adipose tissue, Proteomics, Metabolomics, Mediation analysis
초록	Objectives: Visceral adipose tissue (VAT) is metabolically distinct from subcutaneous fat, but mechanistic pathways linking VAT expansion to chronic kidney disease (CKD) remain poorly characterized. Methods: This study included 343,654 UK Biobank participants who had no CKD at baseline. The main predictor was VAT which was estimated using sex-specific prediction models validated against dual-energy X-ray absorptiometry. Associations between VAT and incident CKD were assessed using multivariable-adjusted Cox proportional hazards models. Mediation analyses (four-way decomposition) were conducted in proteomics (n=29,756) and metabolomics (n=77,945) subcohorts to identify mediating proteins and metabolites. Results: Over a median follow-up of 13.8 years, 12,429 participants (3.6%) developed CKD. VAT showed a graded association with CKD risk. The adjusted hazard ratios (95% confidence intervals) for incident CKD were 1.16 (1.08–1.24), 1.32 (1.24–1.41), and 1.66 (1.56–1.76) for VAT quartiles 2 through 4, respectively. Proteomics analysis identified 35 protein mediators (explaining up to 71% of the VAT-CKD association) enriched in pathways related to angiogenesis, inflammation, and extracellular matrix remodeling. The adipocyte-derived protein FABP4 emerged as the predominant proteomic mediator. Metabolomics identified nine metabolite mediators, with docosahexaenoic acid and lipid unsaturation providing mechanistic evidence of lipid dysregulation. Conclusion: Higher VAT was independently associated with an increased risk of incident CKD, with distinct proteomic and metabolomic signatures implicating angiogenic dysregulation, inflammation, and impaired lipid metabolism. These findings highlight VAT as a modifiable cardiometabolic risk factor and potential therapeutic target for CKD prevention.
원문(PDF)	PDF 원문보기

목록

위로가기